Cancer cell
Immune-Oncology Assays
- Immunogenic Cell Death
- 2D/3D Tumour Killing Assays (panel of tumour cells available)
- On/off target assay
- CDC
3D Tumour Killing Models: Tools for screening immune or tumour targeted therapeutics
Figure 1: SKOV-3 NLR tumour cells were seeded into 96 well plates, PBMC were added once spheroids were established in the presence of Pembrolizumab or IgG4 control or vehicle (untreated) and imaged every 4 hours for 96 hours using the CellCyte X. Relative spheroid area (%) was measured (A). AUC statistics were calculated using GraphPad Prism v9.5.0
Antibody dependent cell cytotoxicity (ADCC) in a 3D tumour spheroid model
Figure 1: SK-OV-3 NLR cells expressing HER2 were plated were seeded into 96 well plates and once spheroids were established purified NK cells were added to cultures in the presence of Trastuzumab or IgG1 Isotype or IL-12/IL-15 or vehicle (untreated) and imaged every 4 hours for 96 hours using the CellCyte X. Relative spheroid area (%) was measured (A) and the AUC (B) calculated using GraphPad Prism v9.5.0. Line graphs show the mean of triplicate wells and the bar graph shows mean +/- SEM of 3 donors. (C) Representative images from the CellCyte X at 96 hours post NK cell addition to tumour spheroids.
Drug Discovery Tool
Find the right immune assay for your therapeutic area, modality and target using this interactive Drug Discovery Tool.